Skip to main content

Advertisement

SpringerLink
Log in

New agents in chronic lymphocytic leukemia

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

For many years, alkylating agents, especially chlorambucil, have been considered the drugs of choice for first-line treatment of progressive and symptomatic chronic lymphocytic leukemia (CLL). More recently, treatment approaches have included purine nucleoside analogs (PNAs), fludarabine or cladribine (2-CdA), and monoclonal anti-bodies (MoAbs). PNAs are highly active in patients with CLL, previously treated and untreated. Significantly higher overall response and complete response in patients treated initially with fludarabine or 2-CdA than in those treated with chlorambucil- or cyclophosphamide-based combination regimens have been recently confirmed in prospective, randomized trials. However, the median survival times do not differ among the patients treated with PNA and alkylating agents. The MoAbs directed against CD52 antigen (alemtuzumab) and CD20 antigen (rituximab) also demonstrate significant activity in CLL and should be used in patients with disease that is refrac-tory to PNAs. Combination therapies with PNAs and cyclophosphamide, and especially with rituximab, are more active than monotherapy with PNAs in regard to response rate and possible survival. Because most patients are older and there is no survival time advantage for alkylating agents or PNA therapies, we recommend chlorambucil as the first-line treatment, with PNAs for consideration as the second-line therapy. PNAs alone or in combination with cyclophosphamide and rituximab as first-line treatment are an option in younger patients, who may be candidates for consolidation therapy with alemtuzumab and/or stem cell transplantation. Alemtuzumab may be an effective treatment for patients refractory to PNAs. Several biological parameters have been gaining increasing importance to evaluate the prognosis of patients with CLL and define optimal therapeutic strategy. Moreover, novel therapies are being evalu-ated, especially in patients refractory to PNAs, including those targeting the anti-apoptotic bcl-2 family of proteins and receptors, vaccines, and allogenic stem cell transplantation, especially after nonmyeloablative chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended

  1. Redaelli A, Laskin BL, Stephens JM, et al.: The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004, 13:279–287.

    Article  CAS  Google Scholar 

  2. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review 1975-2001. Bethesda, MD: National Cancer Institute; 2001.

    Google Scholar 

  3. Dighiero G, Binet JL: When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000, 343:1799–1801.

    Article  PubMed  CAS  Google Scholar 

  4. Chioriazzi N, Rai KR, Ferrarini M: Mechanism of disease: chronic lymphocytic leukemia. N Engl J Med 2005, 352:804–815. This concise review summarizes recent achievements in CLL biology and presents a unifying hypothesis for the develop-ment, growth, and evolution of CLL.

    Article  Google Scholar 

  5. Montserrat E: Classical and new prognostic factors in chronic lymphocytic leukemia: where to now. Hematol J 2002, 3:7–9.

    Article  PubMed  Google Scholar 

  6. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910–1916. This is the most extensive study that presented the prognostic significance of chromosomal abnormalities detected by FISH in CLL.

    Article  PubMed  CAS  Google Scholar 

  7. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indi-cators in chronic lymphocytic leukemia. Blood 1999, 94:1840–1847. This study demonstrates that CLL may originate from preger-minal or postgerminal center B cells. Patients with CLL arising from pregerminal center B cells have a more aggressive disease. This is also the first report that described CD38 expression as an important prognostic factor for CLL.

    PubMed  CAS  Google Scholar 

  8. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848–1854. This study, simultaneously with the study by Damle et al. [7-], highlights the prognostic significance of somatic immunoglo-bulin gene mutation status.

    PubMed  CAS  Google Scholar 

  9. Wagner SD, Cwynarski K: Chronic lymphocytic leukemia: new biological markers for assessing prognosis. Hematol J 2004, 5:197–201.

    Article  PubMed  CAS  Google Scholar 

  10. Hamblin TJ, Orchard JA, Ibbotson RE, et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023–1029.

    Article  PubMed  CAS  Google Scholar 

  11. Thunberg U, Johnson A, Roos G, et al.: CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001, 97:1892–1894.

    Article  PubMed  CAS  Google Scholar 

  12. Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639–1647.

    Article  PubMed  CAS  Google Scholar 

  13. Chen L, Widhopf G, Huynh L, et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100: 4609–4614.

    Article  PubMed  CAS  Google Scholar 

  14. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764–1775. This study showed that CLL patients with ZAP-7 overexpress-ing have a poor clinical outcome. Moreover, this study high-lights the good correlations of ZAP-70 to the somatic mutation status of the CLL cells.

    Article  PubMed  CAS  Google Scholar 

  15. Wiestner A, Rosenwald A, Barry TS, et al.: ZAP-70 expres-sion identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clini-cal outcome and distinct gene expression profile. Blood 2003, 101: 4944–4951.

    Article  PubMed  CAS  Google Scholar 

  16. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893–901.

    Article  PubMed  CAS  Google Scholar 

  17. Orchard JA, Ibbotson R, Devis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 2004, 363:105–111.

    Article  PubMed  CAS  Google Scholar 

  18. Schultze JL, Donovan JW, Gribben JG: Minimal residual disease detection after myeloablative chemotherapy in chronic lymphotic leukemia. J Mol Med 1999, 77:259–265.

    Article  PubMed  CAS  Google Scholar 

  19. Ritgen M, Bottcher S, Dreger P, Knaba M: Evaluation of minimal residual disease in chronic lymphocytic leukemia. Haematologica Res 2005, 1(Suppl 2):5–8.

    Google Scholar 

  20. Magnac C, Sutton L, Cazin B, et al.: Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999, 41: 13–18.

    Article  PubMed  CAS  Google Scholar 

  21. Pfitzner T, Reiser M, Barth S, et al.: Quantitative molecular monitoring of residual tumor cells in chronic lympho-cytic leukemia. Ann Hematol 2002, 81: 258–266

    Article  PubMed  CAS  Google Scholar 

  22. Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lympho-cytic leukemia after alemtuzumab therapy is associ-ated with prolonged survival. J Clin Oncol 2005, 23:2971–2979. This study demonstrated that MRD-negative remission in CLL patients is achievable with alemtuzumab, resulting in an improved overall and treatment-free survival.

    Article  PubMed  CAS  Google Scholar 

  23. Robak T, Kasznicki M: Alkylating agents and nucleo-side analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002, 16:1015–1027.

    Article  PubMed  CAS  Google Scholar 

  24. Nicolle A, Proctor SJ, Summerfield GP: High dose chlorambucil in the treatment of lymphoid malignan-cies. Leuk Lymphoma 2004, 45:271–275.

    Article  PubMed  CAS  Google Scholar 

  25. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists Collaborative Group. J Natl Cancer Inst 1999, 91: 861–868.

  26. Bergmann MA, Goebeler ME, Herold M, et al.: Efficacy of bendamustine in patients with relapsed or refrac-tory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haemato-logica 2005, 90:1357–1364.

    CAS  Google Scholar 

  27. Robak T, Korycka A, Kasznicki M, et al.: Purine nucleo-side analogues for the treatment of hematological malignancies: pharmacology and clinical applica-tions. Curr Cancer Drug Targets 2005, 5:421–444.

    Article  PubMed  CAS  Google Scholar 

  28. Robak T, Blonski JZ, Kasznicki M, et al.: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96:2723–2729. An important randomized study demonstrating the significant activity of cladribine and prednisone over chlorambucil and prednisone therapy as first-line treatment in CLL. Similar to flu-darabine, cladribine is associated with superior response rates, remission duration, and progression-free survival compared with chlorambucil, but no survival advantage was observed.

    PubMed  CAS  Google Scholar 

  29. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750–1757. The first randomized trial comparing fludarabine with chlorambucil in previously untreated CLL patients. The study demonstrated more frequent and durable responses after fludarabine but no survival benefits.

    Article  PubMed  CAS  Google Scholar 

  30. Johnson S, Smith AG, Loffler H, et al.: Multicentre pros-pective randomised trial of fludarabine versus cyclo-phosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996, 347:1432–1438.

    PubMed  CAS  Google Scholar 

  31. Leporrier M, Chevret S, Cazin B, et al.: French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and CHOP in 938 pre-viously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319–2325.

    Article  PubMed  CAS  Google Scholar 

  32. Jaksic B, Brugiatelli M, Suciu S, et al.: Fludarabine versus high-dose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC random-ized trial [abstract P 096]. Haematol Cell Ther 2000, 42:97.

    Google Scholar 

  33. Karlsson K, Stromberg M, Jonsson V, et al.: Cladribine (CdA), fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptom-atic chronic lymphocytic leukemia. First interim analy-sis of data from the international randomized phase III trial [abstract 3470]. Blood 2004, 104( Suppl 1 ): 945a.

    Google Scholar 

  34. Robak T, Blonski JZ, Góra-Tybor J, et al.: Cladribine with cyclophosphamide v.s. fludarabine with cyclophos-phamide as first-line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study (PALG CLL3) [abstract 364]. Hematologica 2005, 90(Suppl 2):143–144.

    Google Scholar 

  35. Rossi JF, van Hoof A, De Boeck K, et al.: Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004, 22:1260–1267.

    Article  PubMed  CAS  Google Scholar 

  36. Boogaerts MA: Oral fludarabine therapy in chronic lym-phocytic leukemia--increased convenience. Hematology 2004, 5(Suppl 1):S31-S37.

    CAS  Google Scholar 

  37. Eichhorst B, Busch R, Hopfinger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107: 885–891. The first randomized trial demonstrating higher activity of flu-darabine combined with cyclophosphamide over fludarabine alone in younger, previously untreated CLL patients.

    Article  PubMed  CAS  Google Scholar 

  38. Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002, 11 9 : 976–984.

    Article  Google Scholar 

  39. Robak T, Blonski JZ, Góra-Tybor J, et al.: Cladribine alone or in combination with cyclophosphamide or cyclo-phosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of prospective, randomized study [abstract 337]. Blood 2004, 104(Suppl 1):100a.

    Google Scholar 

  40. Weiss MA, Maslak PG, Jurcic JG, et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003, 21: 1278–1284.

    Article  PubMed  CAS  Google Scholar 

  41. Byrd JC, Smith L, Hackbarth ML, et al.: Interphase cyto-genetic abnormalities in chronic lymphocytic leuke-mia may predict response to rituximab. Cancer Res 2003, 63:36–38.

    PubMed  CAS  Google Scholar 

  42. O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165–2170.

    PubMed  Google Scholar 

  43. Schulz H, Klein SK, Rehwald U, et al.: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002, 100: 3115–3120.

    Article  PubMed  CAS  Google Scholar 

  44. Savage DG, Cohen NS, Hesdorffer CS, et al.: Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003, 44:477–481.

    Article  PubMed  Google Scholar 

  45. Byrd JC, Peterson BL, Morrison VA, et al.: Randomized phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB9712). Blood 2003, 101: 6–14.

    Article  PubMed  CAS  Google Scholar 

  46. Keating MJ, O'Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclo-phosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079–4088.

    Article  PubMed  CAS  Google Scholar 

  47. The first report that summarized the results of fludarabine, cyclophosphamide, and rituximab (FCR) in 224 previously untreated CLL patients. Extraordinary clinical response was observed, with CR in 70% and OR in 95%.

  48. Wierda W, O'Brien S, Wen S, et al.: Chemoimmunother-apy with fludarabine, cyclophosphamide and ritux-imab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070–4078. This report summarizes the activity of an FCR regimen in 177 previously treated CLL patients, 82% of whom had relapsed after prior fludarabine-based therapy.

    Article  PubMed  CAS  Google Scholar 

  49. Byrd JC, Rai K, Peterson BL, et al.: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49–53. A recent retrospective review of the Cancer and Leukemia Group B 9011 and 9712 trials showing that previously untreated CLL patients who received fludarabine and ritux-imab (compared with patients who received fludarabine alone) experienced significantly higher OR and CR, and longer 2-year OS.

    Article  PubMed  CAS  Google Scholar 

  50. Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multi-center study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lym-phocytic Leukemia. J Clin Oncol 1997, 15:1567–1574.

    PubMed  CAS  Google Scholar 

  51. Rai KR, Freter CE, Mercier RJ, et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002, 20:3891–3897.

    Article  PubMed  CAS  Google Scholar 

  52. Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-LL). Blood 2002, 100: 768–3. This study presents the results of subcutaneous administration of alemtuzumab in patients with previously untreated CLL.

    Article  PubMed  CAS  Google Scholar 

  53. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554–561. This prospective phase II trial investigated the efficacy, safety, and clinical benefit of alemtuzumab for patients with relapsed or refractory CLL.

    Article  PubMed  CAS  Google Scholar 

  54. Rawstron AC, Kennedy B, Moreton P, et al.: Early predic-tion of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004, 103: 2027–031.

    Article  PubMed  CAS  Google Scholar 

  55. Ferrajoli A, O'Brien SM, Cortes JE, et al.: Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003, 98:773–78.

    Article  PubMed  CAS  Google Scholar 

  56. Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leuke-mia with p53 mutations and deletions. Blood 2004, 103: 3278–281. The study demonstrates the efficacy of alemtuzumab in treat-ment of patients with CLL and p53 mutations and deletion.

    Article  PubMed  CAS  Google Scholar 

  57. Elter T, Borchmann P, Schulz H, et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024–031.

    Article  PubMed  CAS  Google Scholar 

  58. Mavromatis BH, Cheson BD: Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004, 18:137–48.

    Article  PubMed  Google Scholar 

  59. Wierda WG, Kipps TJ, Keating MJ: Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:6325–6332.

    Article  PubMed  CAS  Google Scholar 

  60. Rai KR, Moore JO, Boyd TE, et al.: Chemotherapy with or without oblimersen sodium (Bcl-2 antisense, gena-sense, G3139) in advanced CLL: report of a large randomized study [abstract P94]. Leuk Lymphoma 2005, 46(Suppl 1):585.

    Google Scholar 

  61. Rizouli V, Gribben J: The role of stem cell transplanta-tion in chronic lymphocytic leukemia. Semin Hematol 2004, 41: 246–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Medical University of Lodz, Pabianicka 62, 93-513, Lodz, Poland

    Tadeusz Robak MD, PhD

Authors
  1. Tadeusz Robak MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robak, T. New agents in chronic lymphocytic leukemia. Curr. Treat. Options in Oncol. 7, 200–212 (2006). https://doi.org/10.1007/s11864-006-0013-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0013-x

Keywords

Search

Navigation